(as of June 16, 2021)

(as of June 16, 2021)

(as of June 16, 2021)

 (As of June 22, 2021)
The ID and Password are same as the “Program and Abstract Book App. (e-Book)” which has been sent on June 22 to registered E-mail address.

Special Lecture

Risk and Benefit on Vaccine or Nonvaccine Therapeutic Interventions for COVID-19
Kenneth Hastings(Hastings Toxicology Consulting LLC, Former FDA)

Development Challenges for Carcinogenicity Risk Assessments of Topical Drugs
Brett D Hollingshead(Pfizer Drug Safety Research and Development, USA)

Educational Lecture

Computational toxicology and the regulatory environment – past, present, and future
David R Woolley(ForthTox Limited, UK)

The US FDA’s Coronavirus Treatment Acceleration Program (CTAP) and Considerations for Pre-IND Meeting Requests
Integrated Review Process within the Office of New Drugs

Stephanie Leuenroth-Quinn(US FDA)

Streamlined Development Approach to Evaluating Severely debilitating or lifethreatening indications (SDLTs) Therapeutics and Vaccines
Judith Prescott(Merck & Co., Inc., USA)

The Coming Conquest of COVID
Robert W. Amler(New York Medical College, USA)


JSOT-SOT Exchange Promotion Program
ACT/JSOT Joint Session : Nonvaccine Therapeutic Interventions for COVID-19

Note: Only English sessions are listed above

  • Oral Sessions
  • Poster Sessions